Wk Ahead: CELC PDUFA; Med Confs (ISTH, AACI, ASRS); ESMO Regular Titles Jul 17

Research evidence excerpt

Wk Ahead: CELC PDUFA; Med Confs (ISTH, AACI, ASRS); ESMO Regular Titles Jul 17

USA | Biotechnology EquityJulyResearch13, 2026

Wk Ahead: CELC PDUFA; Med Confs (ISTH,

AACI, ASRS); ESMO Regular Titles Jul 17

CELC's 2L PIK3CA WT mBC PDUFA is 7/17 (stock +10-15%/-50%). ESMO

titles for reg abstracts expected online by July 17. ISTH mtg (July 11-14),

where COAG has multiple presentations. ASRS kicks off this wk (July 15-18),

where KOD has GLOW cross-trial comparison data. AAIC also begins this wk

(July 12-15): BIIB will present results from its Tau-targeting ASO Diranersen in

Alzheimer's w/ some readthrough to ARWR's ARO-MAPT.

Med confs this wk

International Society on Thrombosis & Haemostasis (ISTH; note) (July 11-14):•

COAG has 9 presentations on their 2 lead programs sutacimig (GT & FVIID) & •

HMB-002 (VWD) and newly disclosed 3rd program HMB-003. At the conf, there are

competitive updates expected from INCY (Star's) VWD program July 13, 10:00 – 10:15

a.m. CEST

American Society of Retina Specialists (ASRS) (July 15-July 18):•

KOD (Presentation): Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First- •

time, Primary Endpoint Results from the Phase 3 GLOW2 Trial

KOD (Papers on Demand): Intravitreal Tarcocimab Tedromer for Diabetic •

Retinopathy: First-Time Cross Trial Evaluation of the GLOW and...

Roche (Papers on Demand): Efficacy and Safety of Vamikibart in Patients With Uveitic •

Macular Edema: Pooled Results From the Phase 3 MEERKAT and SANDCAT Trials

Roche (Papers on Demand): The Molecular Pathophysiology of Uveitic Macular •

Edema: An Exploratory Analysis From the DOVETAIL Vamikibart

EYPT (Papers on Demand): DAVIO 2 Phase 2 Trial of Bioerodible EYP-1901 (Vorolanib •

Intravitreal Insert) in Wet AMD: Post Hoc Analysis in